Providers Clinical Support System – Substance Use Disorder Treatment (PCSS-SUD Treatment) | TI 26 002

PCSS-SUD Treatment Grant (SAMHSA) - Frequently Asked Questions

What is the PCSS-SUD Treatment grant?

The Providers Clinical Support System - Substance Use Disorder Treatment (PCSS-SUD Treatment) grant is a discretionary funding opportunity from the Substance Abuse and Mental Health Services Administration (SAMHSA). It is focused on expanding the clinical capacity of the healthcare workforce to address substance use disorders (SUD) by providing training, technical assistance, mentoring, and ongoing implementation support.

What is the main purpose of this funding opportunity?

The central aim is to help clinicians more effectively identify substance use disorders and provide evidence-based treatment. The opportunity places particular emphasis on opioid use disorder and alcohol use disorder.

What types of activities does the grant support?

Supported activities include structured trainings, targeted technical assistance, mentorship models (such as clinician-to-clinician consultation), and continued follow-up support. The intent is to build practical skills and help providers apply learning in real-world practice over time.

Is this grant meant to be a one-time training program?

No. The funded effort is expected to function as a national or broadly scaled support and education resource that provides ongoing implementation support and follow-up, rather than one-time instruction alone.

Who is the intended audience for the training and support?

The program is designed for healthcare professionals working in both general medical settings and behavioral health settings. The overall focus is on clinicians who need practical capacity to identify and treat SUD using evidence-based approaches.

What does it mean that this opportunity is a cooperative agreement?

This opportunity is offered as a cooperative agreement, which typically means SAMHSA expects an active federal role and collaboration with the award recipient during the project period.

Is the program expected to be national in scope?

Yes. The announcement indicates the funded effort is expected to operate as a national or broadly scaled support and education resource to reach clinicians across disciplines and care settings.

Who is eligible to apply?

Eligibility is limited to domestic public and private nonprofit entities. The description notes this includes, but is not limited to, professional organizations, including those recognized in connection with the MATE Act.

Are for-profit organizations eligible to apply?

The eligibility statement provided limits applicants to domestic public and private nonprofit entities. Based on that description, for-profit entities are not included as eligible applicants.

What is the MATE Act reference about?

The opportunity notes that eligible applicants include professional organizations recognized in connection with the MATE Act, which relates to training requirements around substance use disorders for certain prescribers.

What is the CFDA number for this opportunity?

The opportunity is listed under CFDA number 93.490.

What funding activity category does this grant fall under?

It falls under the health funding activity category, reflecting a workforce development and clinical practice improvement focus rather than direct service delivery alone.

What is the funding opportunity number?

The funding opportunity number is TI 26 002.

When was the opportunity posted?

The posting (creation) date listed is May 15, 2026.

What is the application deadline?

The original application closing date is June 15, 2026.

How many awards does SAMHSA expect to make?

SAMHSA expects to make one award under this announcement.

What is the maximum award amount (ceiling)?

The award ceiling is $3,000,000.

What does it suggest that SAMHSA plans to make only one award?

The structure suggests SAMHSA is seeking a single lead organization capable of coordinating a comprehensive training and support system, potentially through partnerships, networks, or multi-component programming that can reach clinicians broadly.

Is this opportunity primarily about expanding direct patient services?

The information provided emphasizes workforce development, clinical training, mentoring, and implementation support to improve treatment access and quality over time, rather than direct service delivery alone.

What kinds of support beyond training are expected?

Beyond training sessions, the program description highlights targeted technical assistance, mentorship and consultation models, and continued follow-up support to help providers sustain practice changes and implement evidence-based treatment effectively.